Determination of nontoxic concentrations of piperacillin/tazobactam for intravitreal application an electroretinographic, histopathologic and morphometric analysis

Ophthalmic Research

Volumn 36, Issue 3, 2004, Pages 139-144

  Özkiriş, Abdullah ^a,b   Evereklioglu, Cem ^a   Kontaş, Olgun ^a   Öner, Ayşe Öztürk ^a   Erkiliç, Kuddusi ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Intravitreal injection; Piperacillin tazobactam; Retinal toxicity

Indexed keywords

PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; B WAVE; CELL COUNT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MEGADOSE; ELECTRORETINOGRAM; ENDOPHTHALMITIS; ENUCLEATION; EVALUATION; GANGLION; HISTOPATHOLOGY; MORPHOMETRICS; NERVE CELL; NIGHT VISION; NONHUMAN; PHOTOPIC VISION; PRIORITY JOURNAL; RABBIT; RETINA; STATISTICAL SIGNIFICANCE; TISSUE SECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; ENZYME INHIBITORS; INJECTIONS; OSMOLAR CONCENTRATION; PENICILLANIC ACID; PIPERACILLIN; RABBITS; RETINA; VITREOUS BODY;

EID: 2342630029     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077326     Document Type: Article

References (33)

1. Endophthalmitis Vitrectomy Study Group: Results of the endophthalmitis vitrectomy study. Arch Ophthalmol 1995;113:1479-496.
2. Robinet A, Le Bot MA, Colin J, Riche C: Penetration of piperacillin into the vitreous after intravenous administration. Retina 1998;18: 526-530.
3. Alfaro DV, Pince K, Park J, Runyan T, Ryan SJ, Liggett PE: Systemic antibiotic prophylaxis in penetrating ocular injuries: An experimental study. Retina 1992;12:S3-S6.
4. Doft BH, Kelsey SF, Wisniewski S, Metz DJ, Lobes L, Rinkoff J, Davis M, Kassoff A: Treatment of endophthalmitis after cataract extraction. Retina 1994;14:297-304.
5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-1673.
6. Regal RE, DePestel DD, VandenBussche HL: The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003;23:618-624.
7. Fass RJ: Statistical comparison of the antibacterial activities of broad-spectrum penicillins against Gram-negative bacilli. Antimicrob Agents Chemother 1983;24:156-162.
8. Sanders WE, Sanders CC: Piperacillin/tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996;22:107-123.
9. Okereke C, Dudley MN: Beta-lactam/beta-lactamase inhibitor combinations: Pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. J Antimicrob Chemother 1998; 41:43-49.
10. Platsouka E, Zissis NP, Portolos J, Paniara O: Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review. J Chemother 2003;15:27-30.
11. Powell LL, Wilson SE: The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Surg Infect 2000;1: 57-63.
12. Acar JF, Goldstein FW, Kitzis MD: Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993;31:23-28.
13. Bryson HM, Brogden RN: Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-535.
14. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P: Piperacillin/tazobactam versus imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998;31:355-368.
15. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, Martinez-Pellus A, Palomar M, Barcenilla F: Efficacy and tolerability of piperacillin/ tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial. Intensive Care Med 2001;27:493-502.
16. Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, Haapiainen R, Matikainen M, Laitinen S: Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-261.
17. File TM Jr, Tan JS: Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections. Eur J Surg 1994;573:51-55.
18. Shlaes DM, Baughman R, Boylen CT, Chan JC, Charan NB, Cormier YC, Erickson A, Grossman R, Kirmani N, Suh B: Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;34:565-577.
19. Er H, Doganay S, Evereklioglu C, Turkoz Y, Gunduz A, Borazan M, Ozyalin F: Comparison of the effects of argon and neodymium:YAG laser iridotomy on cytokines in the rabbit aqueous humor. Eur J Ophthalmol 2002;12: 183-187.
20. Er H, Doganay S, Turkoz Y, Cekmen M, Daglioglu MC, Gunduz A, Evereklioglu C, Isci N: The levels of cytokines and nitric oxide in rabbit vitreous humor after retinal laser photocoagulation. Ophthalmic Surg Lasers 2000;31: 479-483.
21. Evereklioglu C, Ozkiris A, Alasehirli B, Sari I, Guldur E, Cengiz B, Kontas O: Effect of gestational nicotine treatment on newborn rat retina: A histopathological and morphometric analysis. Ophthalmic Physiol Opt 2003;23: 527-533.
22. Marrakchi-Benjaafar S, Cochereau I, Pocidalo JJ, Carbon C: Systemic prophylaxis of experimental staphylococcal endophthalmitis: Comparative efficacy of sparfloxacin, pefloxacin, imipenem, vancomycin, and amikacin. J Infect Dis 1995;172:1312-1316.
23. Perry CM, Markham A: Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs 1999;57: 805-843.
24. Kennedy HF, Gemmell CG, Bagg J, Gibson BE, Michie JR: Antimicrobial susceptibility of blood culture isolates of viridans streptococci: Relationship to a change in empirical antibiotic therapy in febrile neutropenia. J Antimicrob Chemother 2001;47:693-696.
25. Ambrose PG, Bhavnani SM, Jones RN: Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: Report from the ARREST Program. Antimicrob Agents Chemother 2003;47:1643-1646.
26. Platsouka E, Zissis NP, Constantoulaki S, Paniara O: Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital. J Chemother 1997;9:336-340.
27. Kroschinsky F, Wichmann G, Bornhauser M, Ordemann R, Schuler U, Ehninger G, Hanel M: Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transpl Infect Dis 2002;4:132-136.
28. Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordmann P: Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallobeta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2032-2034.
29. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP: Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 2002;48:59-63.
30. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H: Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996;40:139-145.
31. Chimura T, Hirayama T: Clinical study of tazobactam/piperacillin in obstetrics and gynecological infections. Jpn J Antibiot 1996;49: 808-812.
32. Naber KG, Savov O, Salmen HC: Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002;19:95-103.
33. Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, Jourdan E, Boiron JM, Reiffers J: A randomized prospective multicentre trial of cefpirome versus piperacillintazobactam in febrile neutropenia. Leuk Lymphoma 2001;42:379-386.